Click Here to
Subscribe
Breaking
News, Updates,
& More
Stay Up
to Date

Nubeqa New Oral Therapy FDA Approved for Nonmetastatic Prostate Cancer

Web Exclusives - FDA Updates

On July 30, 2019, the FDA approved darolutamide (Nubeqa; Bayer HealthCare), an oral androgen receptor inhibitor, for the treatment of patients with nonmetastatic castration-resistant prostate cancer (CRPC). This approval was based on a multicenter, double-blind, placebo-controlled clinical trial known as ARAMIS. The FDA granted this application priority review.

“Patients at this stage of prostate cancer typically don’t have symptoms of the disease. The overarching goals of treatment in this setting are to delay the spread of prostate cancer and limit the burdensome side effects of therapy,” Matthew Smith, MD, PhD, Director, Genitourinary Malignancies Program, Massachusetts General Hospital Cancer Center, said in a statement.

The study included 1509 patients with nonmetastatic CRPC who were randomized in a 2:1 ratio to darolu­tamide or to placebo. In addition, all patients received a gonadotropin-releasing hormone analog unless they previously had a bilateral orchiectomy.

The primary end point was metastasis-free survival. The median metastasis-free survival was 40.4 months (95% confidence interval [CI], 34.3 months-not reached) with darolutamide versus 18.4 months (95% CI, 15.5-22.3 months) with placebo (hazard ratio, 0.41; 95% CI, 0.34-0.50; P <.0001). The overall survival data were not yet mature at the FDA approval.

The most common (≥2%) adverse events with darolutamide were fatigue, extremity pain, and rash. Ischemic heart disease (4.3%) and heart failure (2.1%) were more common with darolutamide than with placebo.

Related Items
November 11, 2019 — Oncology News & Updates
Web Exclusives published on November 11, 2019 in FDA Updates, In the News
Zejula Receives FDA Approval for HRD-Positive Advanced Ovarian Cancer
Web Exclusives published on November 7, 2019 in FDA Updates, Ovarian Cancer
Turalio First FDA-Approved Systemic Therapy for Tenosynovial Giant-Cell Tumor
Web Exclusives published on October 29, 2019 in FDA Updates
Rozlytrek Third FDA-Approved Tumor-Agnostic Drug and Second Treatment for Patients with NTRK Fusion Tumors
Web Exclusives published on October 29, 2019 in FDA Updates
October 28, 2019 – Oncology News & Updates
Web Exclusives published on October 28, 2019 in FDA Updates, In the News, Ovarian Cancer
Vincristine, Racial Disparities in Multiple Myeloma, and HER2 Metastatic Breast Cancer Are in the News
Web Exclusives published on October 22, 2019 in Breast Cancer, FDA Updates, In the News, Multiple Myeloma, Pediatric Cancer
FDA on In Vitro Diagnostics, Vaping; Cost of Novel Treatments
Web Exclusives published on October 15, 2019 in FDA Updates, In the News, NCCN
FDA Approves Darzalex Combination for First-Line Treatment of Transplant-Eligible Patients with Multiple Myeloma
Web Exclusives published on September 30, 2019 in FDA Updates, Multiple Myeloma, In the News
Polivy FDA Approved for Patients with Relapsed or Refractory DLBCL
Web Exclusives published on September 11, 2019 in FDA Updates, Lymphoma
Keytruda Approved for Patients with Previously Treated Metastatic Small-Cell Lung Cancer
Yvette Florio Lane
Web Exclusives published on June 26, 2019 in FDA Updates, In the News
Last modified: October 29, 2019